Efficacy of New Antituberculosis Drugs in Patients with Extensive Drug Resistance

The study aimed to evaluate the effectiveness of new antituberculosis drugs in patients with extensively drug-resistant tuberculosis. A retrospective analysis of data from 178 patients revealed key findings. One of the main outcomes was the cessation of bacterial excretion in 40.5% of patients after just six months of treatment. However, the therapy was associated with adverse reactions in 46.6% of cases. The most common side effects were gastrointestinal disturbances (21.3%) and hepatological issues (13.5%). Drugs like bedaquiline, linezolid, clofazimine, and fluoroquinolones demonstrated high efficacy, ensuring good patient adherence to treatment. The study confirmed that new chemotherapy regimens significantly improve treatment outcomes and accelerate patient recovery.